Dose response curves for cenicriviroc-dependent inhibition (A) and maraviroc-dependent inhibition (B).

<p>R5, dual and X4-tropic HIV-2 strains are depicted in continuous, dashed and dotted black lines, respectively. HIV-1 R5-tropic strain is depicted using the continuous gray line.</p

Baseline characteristics of the 116 patients.

<p>ART: antiretroviral therapy, ATV: atazanavir, DRV: darunavir, EFV: efavirenz, ETR: etravirine, FTC: emtricitabine, IQR: interquartile range, LPV: lopinavir, MVC: maraviroc, NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors, NVP: nevirapine, PI: protease inhibitors, RAL: raltegravir, TDF: tenofovir, /r: boosted with ritonavir.</p><p>Baseline characteristics of the 116 patients.</p

Distribution of NRTI (a) and NNRTI (b) resistance-associated mutations detected in the historical genotypic resistance tests of the patients.

<p>NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors.</p

Distribution of tenofovir, emtricitabine and rilpivirine plasma concentrations at different time-points.

<p>Distribution of tenofovir, emtricitabine and rilpivirine plasma concentrations at different time-points.</p

Concordance between the 4 methods used to analyze HIV tropism in the 102 patients with UDPS sequences of good quality at D0.

<p>Consensus means that the consensus of UDPS sequences has been used as a surrogate of population sequencing; UDPS means that the full set of pyrosequencing sequences has been used; g2p means that the geno2pheno algorithm has been used for analysis; Pyrotrop means that our in-house software has been used for analysis.</p><p>Concordance between the 4 methods used to analyze HIV tropism in the 102 patients with UDPS sequences of good quality at D0.</p

Baseline characteristics of the 116 patients.

<p>ART: antiretroviral therapy, ATV: atazanavir, DRV: darunavir, EFV: efavirenz, ETR: etravirine, FTC: emtricitabine, IQR: interquartile range, LPV: lopinavir, MVC: maraviroc, NNRTI: non nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse transcriptase inhibitors, NVP: nevirapine, PI: protease inhibitors, RAL: raltegravir, TDF: tenofovir, /r: boosted with ritonavir.</p><p>Baseline characteristics of the 116 patients.</p

HIV serological and molecular testing for dually HIV-1 and HIV-2 diagnosis in West Africa.

HIV serological and molecular testing for dually HIV-1 and HIV-2 diagnosis in West Africa.</p

Correlation between FibroScan® values and inflammatory biomarkers (Spearman rank’s test).

<p>Correlation between FibroScan® values and inflammatory biomarkers (Spearman rank’s test).</p

Characteristics of HIV/HCV co-infected patients (<i>n</i> = 60).

<p>Continuous variables were expressed as medians and interquartile ranges (IQR), and categorical variables were expressed as numbers and percentages.</p><p>ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamyl transpeptidase.</p

Distribution of plasma HIV-1 viral load at baseline (BL), Week (W)12, W24, W36, W48, W72 and W96.

<p>Distribution of plasma HIV-1 viral load at baseline (BL), Week (W)12, W24, W36, W48, W72 and W96.</p